Contact
Please use this form to send email to PR contact of this press release:
Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease
TO:
Please use this form to send email to PR contact of this press release:
Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease
TO: